S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
NASDAQ:VCEL

Vericel Stock Forecast, Price & News

$33.93
+1.10 (+3.35%)
(As of 01/24/2022 12:00 AM ET)
Add
Compare
Today's Range
$31.37
$34.05
50-Day Range
$32.81
$44.33
52-Week Range
$31.36
$68.94
Volume
646,847 shs
Average Volume
692,424 shs
Market Capitalization
$1.59 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.97
30 days | 90 days | 365 days | Advanced Chart
Receive VCEL News and Ratings via Email

Sign-up to receive the latest news and ratings for Vericel and its competitors with MarketBeat's FREE daily newsletter.


Vericel logo

About Vericel

Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.

Headlines

Global Cell and Gene Therapy Market - Yahoo Finance
January 24, 2022 |  finance.yahoo.com
Vericel (NASDAQ:VCEL) Hits New 12-Month Low at $33.88
January 19, 2022 |  americanbankingnews.com
Vericel (NASDAQ:VCEL) Shares Gap Down to $38.58
January 12, 2022 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VCEL
Employees
273
Year Founded
1989

Sales & Book Value

Annual Sales
$124.18 million
Cash Flow
$0.12 per share
Book Value
$2.96 per share

Profitability

Net Income
$3.04 million
Pretax Margin
0.40%

Debt

Price-To-Earnings

Miscellaneous

Free Float
44,662,000
Market Cap
$1.59 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/08/2021
Today
1/25/2022
Next Earnings (Estimated)
2/23/2022
Fiscal Year End
12/31/2022

Social Links


MarketRank

Overall MarketRank

1.85 out of 5 stars

Medical Sector

785th out of 1,415 stocks

Biological Products, Except Diagnostic Industry

125th out of 206 stocks

Analyst Opinion: 3.4Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -












Vericel (NASDAQ:VCEL) Frequently Asked Questions

Is Vericel a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vericel in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Vericel stock.
View analyst ratings for Vericel
or view top-rated stocks.

How has Vericel's stock been impacted by COVID-19?

Vericel's stock was trading at $12.08 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, VCEL stock has increased by 180.9% and is now trading at $33.93.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Vericel?

Vericel saw a increase in short interest in December. As of December 31st, there was short interest totaling 7,130,000 shares, an increase of 40.1% from the December 15th total of 5,090,000 shares. Based on an average daily volume of 438,200 shares, the days-to-cover ratio is presently 16.3 days.
View Vericel's Short Interest
.

When is Vericel's next earnings date?

Vericel is scheduled to release its next quarterly earnings announcement on Wednesday, February 23rd 2022.
View our earnings forecast for Vericel
.

How were Vericel's earnings last quarter?

Vericel Co. (NASDAQ:VCEL) released its quarterly earnings data on Monday, November, 8th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.03) by $0.08. The biotechnology company earned $34.51 million during the quarter, compared to the consensus estimate of $38.07 million. Vericel had a net margin of 0.14% and a trailing twelve-month return on equity of 0.15%. The firm's revenue for the quarter was up 7.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.08 earnings per share.
View Vericel's earnings history
.

What guidance has Vericel issued on next quarter's earnings?

Vericel issued an update on its FY 2021 earnings guidance on Tuesday, December, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $158 million-$161 million, compared to the consensus revenue estimate of $169.84 million.

What price target have analysts set for VCEL?

5 analysts have issued 1-year price targets for Vericel's stock. Their forecasts range from $52.00 to $65.00. On average, they anticipate Vericel's stock price to reach $58.75 in the next twelve months. This suggests a possible upside of 73.2% from the stock's current price.
View analysts' price targets for Vericel
or view top-rated stocks among Wall Street analysts.

Who are Vericel's key executives?

Vericel's management team includes the following people:

What is Nick Colangelo's approval rating as Vericel's CEO?

6 employees have rated Vericel CEO Nick Colangelo on Glassdoor.com. Nick Colangelo has an approval rating of 49% among Vericel's employees. This puts Nick Colangelo in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Vericel own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vericel investors own include Exelixis (EXEL), Novavax (NVAX), Momo (MOMO), Dynavax Technologies (DVAX), Synergy Pharmaceuticals (SGYP), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Verastem (VSTM), Amarin (AMRN) and NVIDIA (NVDA).

What is Vericel's stock symbol?

Vericel trades on the NASDAQ under the ticker symbol "VCEL."

Who are Vericel's major shareholders?

Vericel's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Conestoga Capital Advisors LLC (3.59%), Scout Investments Inc. (0.74%), Russell Investments Group Ltd. (0.30%), New York State Teachers Retirement System (0.10%), State of Alaska Department of Revenue (0.07%) and Curbstone Financial Management Corp (0.02%). Company insiders that own Vericel stock include Dominick Colangelo, Jonathan Mark Hopper, Michael Halpin, Paul K Wotton, Robert L Md Zerbe, Sean C Flynn and Steven C Gilman.
View institutional ownership trends for Vericel
.

Which institutional investors are selling Vericel stock?

VCEL stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Strs Ohio, Scout Investments Inc., and State of Alaska Department of Revenue. Company insiders that have sold Vericel company stock in the last year include Dominick Colangelo, Jonathan Mark Hopper, Michael Halpin, Paul K Wotton, Sean C Flynn, and Steven C Gilman.
View insider buying and selling activity for Vericel
or view top insider-selling stocks.

Which institutional investors are buying Vericel stock?

VCEL stock was bought by a variety of institutional investors in the last quarter, including Conestoga Capital Advisors LLC, Curbstone Financial Management Corp, and New York State Teachers Retirement System.
View insider buying and selling activity for Vericel
or or view top insider-buying stocks.

How do I buy shares of Vericel?

Shares of VCEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vericel's stock price today?

One share of VCEL stock can currently be purchased for approximately $33.93.

How much money does Vericel make?

Vericel has a market capitalization of $1.59 billion and generates $124.18 million in revenue each year. The biotechnology company earns $3.04 million in net income (profit) each year or ($0.01) on an earnings per share basis.

How many employees does Vericel have?

Vericel employs 273 workers across the globe.

When was Vericel founded?

Vericel was founded in 1989.

What is Vericel's official website?

The official website for Vericel is www.vcel.com.

Where are Vericel's headquarters?

Vericel is headquartered at 64 SIDNEY STREET, CAMBRIDGE MA, 02139.

How can I contact Vericel?

Vericel's mailing address is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at (800) 556-0311, via email at [email protected], or via fax at 617-588-5554.


This page was last updated on 1/25/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.